Apellis Pharmaceuticals recently announced new one-year results from the Phase 3 VALIANT study, highlighting sustained efficacy and favorable safety for EMPAVELI in treating rare kidney diseases, including C3 glomerulopathy and IC-MPGN.

Notably, EMPAVELI achieved durable proteinuria reduction and outperformed iptacopan in indirect comparisons, reinforcing its position in a highly specialized nephrology market.

We'll explore how EMPAVELI's competitive edge in rare kidney diseases could influence Apellis Pharmaceuticals' investment narrative and market outlook.

These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

For investors, Apellis Pharmaceuticals offers an innovation-driven story in rare disease treatments, with EMPAVELI’s new one-year Phase 3 results further strengthening the company’s case in a specialized kidney market. While this data reinforces EMPAVELI’s competitive advantages, it does not materially change the current short-term catalyst, successful commercial execution following July’s FDA approval, nor does it diminish significant near-term risks tied to access, funding for co-pay programs, and margin pressure from free drug utilization.

Among recent announcements, the FDA approval of EMPAVELI for C3G and IC-MPGN in July stands out as most relevant, as it marked the first regulatory green light for these indications and sets the stage for EMPAVELI’s launch into a new patient segment. The new data adds confidence for ongoing adoption, but potential headwinds around patient access and net revenue realization remain highly relevant for Apellis’s growth trajectory. Still, investors should also be aware that, in contrast to these clinical milestones, there are funding and reimbursement realities that...

Read the full narrative on Apellis Pharmaceuticals (it's free!)

Apellis Pharmaceuticals is projected to reach $1.2 billion in revenue and $130.6 million in earnings by 2028. This outlook assumes a 16.9% annual revenue growth rate and a $358.8 million increase in earnings from the current level of -$228.2 million.

Uncover how Apellis Pharmaceuticals' forecasts yield a $37.47 fair value, a 31% upside to its current price.

Three Simply Wall St Community fair value estimates for Apellis range from US$37.47 to US$93.90, reflecting wide differences in expectations. With EMPAVELI’s new data, your view on patient access and market expansion could shape how you interpret these contrasting opinions.

Explore 3 other fair value estimates on Apellis Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Apellis Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Our free Apellis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Apellis Pharmaceuticals' overall financial health at a glance.

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include APLS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com